nodes	percent_of_prediction	percent_of_DWPC	metapath
Rasagiline—CYP1A2—Estropipate—osteoporosis	0.147	0.53	CbGbCtD
Rasagiline—CYP1A2—Conjugated Estrogens—osteoporosis	0.0697	0.25	CbGbCtD
Rasagiline—CYP1A2—Estradiol—osteoporosis	0.0612	0.22	CbGbCtD
Rasagiline—BCL2—Fulvestrant—Estradiol—osteoporosis	0.00833	1	CbGdCrCtD
Rasagiline—MAOB—Alpha-synuclein signaling—PARK7—osteoporosis	0.00782	0.0532	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—IBSP—osteoporosis	0.00712	0.0484	CbGpPWpGaD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—GSN—osteoporosis	0.00467	0.0317	CbGpPWpGaD
Rasagiline—BCL2—EPO signaling pathway—RAP1A—osteoporosis	0.00429	0.0292	CbGpPWpGaD
Rasagiline—BCL2—FAS pathway and Stress induction of HSP regulation—ACTG1—osteoporosis	0.00413	0.0281	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—BGLAP—osteoporosis	0.00296	0.0201	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—GSN—osteoporosis	0.00286	0.0195	CbGpPWpGaD
Rasagiline—BCL2—RXR and RAR heterodimerization with other nuclear receptor—VDR—osteoporosis	0.00286	0.0195	CbGpPWpGaD
Rasagiline—BCL2—Role of Calcineurin-dependent NFAT signaling in lymphocytes—NFATC1—osteoporosis	0.00275	0.0187	CbGpPWpGaD
Rasagiline—MAOB—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.00266	0.0181	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—COL1A2—osteoporosis	0.00256	0.0174	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—DKK1—osteoporosis	0.00241	0.0164	CbGpPWpGaD
Rasagiline—BCL2—Estrogen signaling pathway—ESR1—osteoporosis	0.00241	0.0164	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—IBSP—osteoporosis	0.00221	0.015	CbGpPWpGaD
Rasagiline—MAOB—Tryptophan metabolism—CYP19A1—osteoporosis	0.00213	0.0145	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—GSN—osteoporosis	0.0021	0.0143	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—COL1A2—osteoporosis	0.00203	0.0138	CbGpPWpGaD
Rasagiline—BCL2—EPO signaling pathway—IRS2—osteoporosis	0.00198	0.0135	CbGpPWpGaD
Rasagiline—BCL2—Amyotrophic lateral sclerosis (ALS)—GPX1—osteoporosis	0.00197	0.0134	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—WNT1—osteoporosis	0.00185	0.0126	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—TNFRSF11B—osteoporosis	0.00184	0.0125	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—WNT1—osteoporosis	0.0015	0.0102	CbGpPWpGaD
Rasagiline—BCL2—TP53 Network—MYC—osteoporosis	0.00146	0.00994	CbGpPWpGaD
Rasagiline—MAOB—Biological oxidations—CYP27A1—osteoporosis	0.00141	0.00962	CbGpPWpGaD
Rasagiline—MAOB—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.0014	0.00951	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—BMP2—osteoporosis	0.0014	0.00951	CbGpPWpGaD
Rasagiline—BCL2—Overview of nanoparticle effects—TNF—osteoporosis	0.00136	0.00926	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—COL1A1—osteoporosis	0.00131	0.00889	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—IRS2—osteoporosis	0.0013	0.00887	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—DKK1—osteoporosis	0.00127	0.00867	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—TLN1—osteoporosis	0.00125	0.00851	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—RAP1A—osteoporosis	0.00124	0.00843	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—VCL—osteoporosis	0.00123	0.00839	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—ACTG1—osteoporosis	0.00123	0.00839	CbGpPWpGaD
Rasagiline—BCL2—Ceramide signaling pathway—IGF1—osteoporosis	0.00116	0.00788	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—IRS1—osteoporosis	0.00114	0.00774	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—ESR1—osteoporosis	0.00113	0.00772	CbGpPWpGaD
Rasagiline—BCL2—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—osteoporosis	0.00113	0.00771	CbGpPWpGaD
Rasagiline—BCL2—Overview of nanoparticle effects—IL6—osteoporosis	0.0011	0.00747	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—COL1A2—osteoporosis	0.00106	0.0072	CbGpPWpGaD
Rasagiline—BCL2—RXR and RAR heterodimerization with other nuclear receptor—TNF—osteoporosis	0.00106	0.0072	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—RAP1A—osteoporosis	0.00103	0.00701	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	0.00103	0.00699	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by STAT5—MYC—osteoporosis	0.00101	0.0069	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—PSMA5—osteoporosis	0.000967	0.00658	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—PSMA2—osteoporosis	0.000967	0.00658	CbGpPWpGaD
Rasagiline—CYP1A2—Estrogen Receptor Pathway—ESR1—osteoporosis	0.000907	0.00616	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—SOD2—osteoporosis	0.000888	0.00604	CbGpPWpGaD
Rasagiline—BCL2—HIV-1 Nef: Negative effector of Fas and TNF-alpha—TNF—osteoporosis	0.000875	0.00595	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by PI3K—MYC—osteoporosis	0.000857	0.00583	CbGpPWpGaD
Rasagiline—MAOB—Phase 1 - Functionalization of compounds—POMC—osteoporosis	0.000841	0.00572	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—COL1A1—osteoporosis	0.000814	0.00553	CbGpPWpGaD
Rasagiline—BCL2—IL-5 Signaling Pathway—MYC—osteoporosis	0.000806	0.00548	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CYP19A1—osteoporosis	0.000801	0.00545	CbGpPWpGaD
Rasagiline—BCL2—Amyotrophic lateral sclerosis (ALS)—TNF—osteoporosis	0.000782	0.00532	CbGpPWpGaD
Rasagiline—BCL2—IL-2 Signaling Pathway—MYC—osteoporosis	0.000775	0.00527	CbGpPWpGaD
Rasagiline—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.00076	0.00517	CbGpPWpGaD
Rasagiline—CYP1A2—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.00075	0.0051	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—MYC—osteoporosis	0.000746	0.00508	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—TGFB1—osteoporosis	0.000745	0.00506	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—VDR—osteoporosis	0.000744	0.00506	CbGpPWpGaD
Rasagiline—MAOB—Biological oxidations—CYP19A1—osteoporosis	0.000743	0.00505	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—IGF1—osteoporosis	0.00074	0.00503	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	0.000731	0.00497	CbGpPWpGaD
Rasagiline—BCL2—FAS pathway and Stress induction of HSP regulation—TNF—osteoporosis	0.000722	0.00491	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—POMC—osteoporosis	0.000716	0.00487	CbGpPWpGaD
Rasagiline—BCL2—Ceramide signaling pathway—MYC—osteoporosis	0.000696	0.00473	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—GPX1—osteoporosis	0.000693	0.00471	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—TGFB1—osteoporosis	0.000683	0.00465	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—SPP1—osteoporosis	0.000673	0.00457	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—IRS1—osteoporosis	0.000649	0.00441	CbGpPWpGaD
Rasagiline—BCL2—Ceramide signaling pathway—TNF—osteoporosis	0.000649	0.00441	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—MYC—osteoporosis	0.000634	0.00431	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—IL6R—osteoporosis	0.000628	0.00427	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—IGF1—osteoporosis	0.000619	0.00421	CbGpPWpGaD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000616	0.00419	CbGpPWpGaD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—TNF—osteoporosis	0.000565	0.00384	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—MYC—osteoporosis	0.00056	0.00381	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IRAK3—osteoporosis	0.000555	0.00377	CbGpPWpGaD
Rasagiline—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.00055	0.00374	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—ESR1—osteoporosis	0.000535	0.00364	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—SPP1—osteoporosis	0.000527	0.00358	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—ACTG1—osteoporosis	0.000508	0.00345	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—IRS1—osteoporosis	0.0005	0.0034	CbGpPWpGaD
Rasagiline—CYP1A2—Tryptophan metabolism—CYP19A1—osteoporosis	0.000494	0.00336	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—IL1B—osteoporosis	0.000478	0.00325	CbGpPWpGaD
Rasagiline—MAOB—Biological oxidations—POMC—osteoporosis	0.000447	0.00304	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—MYC—osteoporosis	0.000445	0.00303	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—MYC—osteoporosis	0.000445	0.00303	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—IL6—osteoporosis	0.000444	0.00302	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	0.000443	0.00301	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PKM—osteoporosis	0.000421	0.00286	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—FDPS—osteoporosis	0.000421	0.00286	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CTSK—osteoporosis	0.000421	0.00286	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TNF—osteoporosis	0.000414	0.00282	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—NFATC1—osteoporosis	0.000414	0.00281	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—TGFB1—osteoporosis	0.000413	0.00281	CbGpPWpGaD
Rasagiline—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000399	0.00272	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GPD2—osteoporosis	0.000399	0.00272	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PGLS—osteoporosis	0.000399	0.00272	CbGpPWpGaD
Rasagiline—CYP1A2—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000394	0.00268	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—IGF1—osteoporosis	0.000385	0.00262	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	0.000384	0.00261	CbGpPWpGaD
Rasagiline—CYP1A2—Arachidonic acid metabolism—GPX1—osteoporosis	0.000376	0.00256	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—TGFB1—osteoporosis	0.000371	0.00252	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PNP—osteoporosis	0.000365	0.00248	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ATIC—osteoporosis	0.000365	0.00248	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—MYC—osteoporosis	0.000361	0.00246	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—TGFB1—osteoporosis	0.00036	0.00245	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—osteoporosis	0.00033	0.00224	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—CYP27A1—osteoporosis	0.000327	0.00223	CbGpPWpGaD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000324	0.0022	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IRAK3—osteoporosis	0.000323	0.0022	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—CYP27A1—osteoporosis	0.000323	0.0022	CbGpPWpGaD
Rasagiline—Rash—Etidronic acid—osteoporosis	0.000311	0.000549	CcSEcCtD
Rasagiline—Convulsion—Zoledronate—osteoporosis	0.000311	0.000549	CcSEcCtD
Rasagiline—Dermatitis—Etidronic acid—osteoporosis	0.000311	0.000549	CcSEcCtD
Rasagiline—MAOB—Metabolism—CA2—osteoporosis	0.000311	0.00211	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—OXCT1—osteoporosis	0.000311	0.00211	CbGpPWpGaD
Rasagiline—Vertigo—Conjugated Estrogens—osteoporosis	0.00031	0.000548	CcSEcCtD
Rasagiline—Hyperhidrosis—Pamidronate—osteoporosis	0.00031	0.000547	CcSEcCtD
Rasagiline—Syncope—Conjugated Estrogens—osteoporosis	0.00031	0.000547	CcSEcCtD
Rasagiline—Hypertension—Zoledronate—osteoporosis	0.00031	0.000547	CcSEcCtD
Rasagiline—Hypersensitivity—Alendronate—osteoporosis	0.00031	0.000547	CcSEcCtD
Rasagiline—Headache—Etidronic acid—osteoporosis	0.000309	0.000546	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000307	0.000542	CcSEcCtD
Rasagiline—Asthenia—Estropipate—osteoporosis	0.000306	0.00054	CcSEcCtD
Rasagiline—Anorexia—Pamidronate—osteoporosis	0.000306	0.000539	CcSEcCtD
Rasagiline—Chest pain—Zoledronate—osteoporosis	0.000305	0.000539	CcSEcCtD
Rasagiline—Arthralgia—Zoledronate—osteoporosis	0.000305	0.000539	CcSEcCtD
Rasagiline—Insomnia—Risedronate—osteoporosis	0.000305	0.000538	CcSEcCtD
Rasagiline—Anxiety—Zoledronate—osteoporosis	0.000304	0.000537	CcSEcCtD
Rasagiline—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000304	0.000536	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000303	0.000536	CcSEcCtD
Rasagiline—Paraesthesia—Risedronate—osteoporosis	0.000303	0.000535	CcSEcCtD
Rasagiline—MAOB—Metabolism—MGLL—osteoporosis	0.000303	0.00206	CbGpPWpGaD
Rasagiline—Pruritus—Estropipate—osteoporosis	0.000302	0.000533	CcSEcCtD
Rasagiline—Discomfort—Zoledronate—osteoporosis	0.000302	0.000533	CcSEcCtD
Rasagiline—Asthenia—Alendronate—osteoporosis	0.000301	0.000532	CcSEcCtD
Rasagiline—Hypersensitivity—Ibandronate—osteoporosis	0.000301	0.000532	CcSEcCtD
Rasagiline—Cough—Conjugated Estrogens—osteoporosis	0.000301	0.000532	CcSEcCtD
Rasagiline—Dyspnoea—Risedronate—osteoporosis	0.000301	0.000531	CcSEcCtD
Rasagiline—Hypotension—Pamidronate—osteoporosis	0.0003	0.000529	CcSEcCtD
Rasagiline—Convulsion—Conjugated Estrogens—osteoporosis	0.000299	0.000528	CcSEcCtD
Rasagiline—Dry mouth—Zoledronate—osteoporosis	0.000299	0.000527	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000299	0.000527	CcSEcCtD
Rasagiline—Pruritus—Alendronate—osteoporosis	0.000297	0.000525	CcSEcCtD
Rasagiline—Dyspepsia—Risedronate—osteoporosis	0.000297	0.000524	CcSEcCtD
Rasagiline—Eye disorder—Estradiol—osteoporosis	0.000297	0.000524	CcSEcCtD
Rasagiline—Constipation—Ethinyl Estradiol—osteoporosis	0.000296	0.000522	CcSEcCtD
Rasagiline—BCL2—Immune System—ACTG1—osteoporosis	0.000296	0.00201	CbGpPWpGaD
Rasagiline—Confusional state—Zoledronate—osteoporosis	0.000295	0.000521	CcSEcCtD
Rasagiline—Hypersensitivity—Calcitriol—osteoporosis	0.000295	0.000521	CcSEcCtD
Rasagiline—Cardiac disorder—Estradiol—osteoporosis	0.000295	0.00052	CcSEcCtD
Rasagiline—Arthralgia—Conjugated Estrogens—osteoporosis	0.000294	0.000519	CcSEcCtD
Rasagiline—Chest pain—Conjugated Estrogens—osteoporosis	0.000294	0.000519	CcSEcCtD
Rasagiline—Asthenia—Ibandronate—osteoporosis	0.000294	0.000518	CcSEcCtD
Rasagiline—Anxiety—Conjugated Estrogens—osteoporosis	0.000293	0.000517	CcSEcCtD
Rasagiline—Nausea—Etidronic acid—osteoporosis	0.000293	0.000517	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000292	0.000516	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000292	0.000516	CcSEcCtD
Rasagiline—Diarrhoea—Estropipate—osteoporosis	0.000292	0.000515	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Risedronate—osteoporosis	0.000291	0.000514	CcSEcCtD
Rasagiline—Infection—Zoledronate—osteoporosis	0.000291	0.000514	CcSEcCtD
Rasagiline—Insomnia—Pamidronate—osteoporosis	0.00029	0.000512	CcSEcCtD
Rasagiline—Pruritus—Ibandronate—osteoporosis	0.000289	0.000511	CcSEcCtD
Rasagiline—Constipation—Risedronate—osteoporosis	0.000288	0.000509	CcSEcCtD
Rasagiline—Angiopathy—Estradiol—osteoporosis	0.000288	0.000509	CcSEcCtD
Rasagiline—Shock—Zoledronate—osteoporosis	0.000288	0.000509	CcSEcCtD
Rasagiline—Paraesthesia—Pamidronate—osteoporosis	0.000288	0.000508	CcSEcCtD
Rasagiline—Diarrhoea—Alendronate—osteoporosis	0.000288	0.000508	CcSEcCtD
Rasagiline—Asthenia—Calcitriol—osteoporosis	0.000287	0.000507	CcSEcCtD
Rasagiline—Nervous system disorder—Zoledronate—osteoporosis	0.000287	0.000507	CcSEcCtD
Rasagiline—Immune system disorder—Estradiol—osteoporosis	0.000287	0.000506	CcSEcCtD
Rasagiline—Mediastinal disorder—Estradiol—osteoporosis	0.000286	0.000505	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—KL—osteoporosis	0.000286	0.00194	CbGpPWpGaD
Rasagiline—Dyspnoea—Pamidronate—osteoporosis	0.000286	0.000505	CcSEcCtD
Rasagiline—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000285	0.000503	CcSEcCtD
Rasagiline—Chills—Estradiol—osteoporosis	0.000285	0.000503	CcSEcCtD
Rasagiline—Somnolence—Pamidronate—osteoporosis	0.000285	0.000503	CcSEcCtD
Rasagiline—Skin disorder—Zoledronate—osteoporosis	0.000284	0.000502	CcSEcCtD
Rasagiline—Pruritus—Calcitriol—osteoporosis	0.000283	0.0005	CcSEcCtD
Rasagiline—Hyperhidrosis—Zoledronate—osteoporosis	0.000283	0.0005	CcSEcCtD
Rasagiline—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000283	0.000499	CcSEcCtD
Rasagiline—Diarrhoea—Raloxifene—osteoporosis	0.000283	0.000499	CcSEcCtD
Rasagiline—Dyspepsia—Pamidronate—osteoporosis	0.000282	0.000498	CcSEcCtD
Rasagiline—Dizziness—Estropipate—osteoporosis	0.000282	0.000498	CcSEcCtD
Rasagiline—Alopecia—Estradiol—osteoporosis	0.000281	0.000495	CcSEcCtD
Rasagiline—Infection—Conjugated Estrogens—osteoporosis	0.00028	0.000495	CcSEcCtD
Rasagiline—Diarrhoea—Ibandronate—osteoporosis	0.00028	0.000494	CcSEcCtD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—IL6—osteoporosis	0.00028	0.0019	CbGpPWpGaD
Rasagiline—Anorexia—Zoledronate—osteoporosis	0.000279	0.000493	CcSEcCtD
Rasagiline—Decreased appetite—Pamidronate—osteoporosis	0.000279	0.000492	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—MYC—osteoporosis	0.000278	0.00189	CbGpPWpGaD
Rasagiline—Mental disorder—Estradiol—osteoporosis	0.000278	0.000491	CcSEcCtD
Rasagiline—Dizziness—Alendronate—osteoporosis	0.000278	0.000491	CcSEcCtD
Rasagiline—Shock—Conjugated Estrogens—osteoporosis	0.000277	0.00049	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000277	0.000489	CcSEcCtD
Rasagiline—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000276	0.000488	CcSEcCtD
Rasagiline—Malnutrition—Estradiol—osteoporosis	0.000276	0.000488	CcSEcCtD
Rasagiline—Gastrointestinal pain—Risedronate—osteoporosis	0.000276	0.000487	CcSEcCtD
Rasagiline—Urticaria—Ethinyl Estradiol—osteoporosis	0.000275	0.000485	CcSEcCtD
Rasagiline—Constipation—Pamidronate—osteoporosis	0.000274	0.000484	CcSEcCtD
Rasagiline—Diarrhoea—Calcitriol—osteoporosis	0.000274	0.000484	CcSEcCtD
Rasagiline—Skin disorder—Conjugated Estrogens—osteoporosis	0.000274	0.000483	CcSEcCtD
Rasagiline—Hypotension—Zoledronate—osteoporosis	0.000274	0.000483	CcSEcCtD
Rasagiline—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000273	0.000483	CcSEcCtD
Rasagiline—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000273	0.000483	CcSEcCtD
Rasagiline—Dizziness—Raloxifene—osteoporosis	0.000273	0.000483	CcSEcCtD
Rasagiline—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000273	0.000481	CcSEcCtD
Rasagiline—Flatulence—Estradiol—osteoporosis	0.000272	0.000481	CcSEcCtD
Rasagiline—Vomiting—Estropipate—osteoporosis	0.000271	0.000479	CcSEcCtD
Rasagiline—Dysgeusia—Estradiol—osteoporosis	0.000271	0.000478	CcSEcCtD
Rasagiline—Dizziness—Ibandronate—osteoporosis	0.000271	0.000478	CcSEcCtD
Rasagiline—Rash—Estropipate—osteoporosis	0.000269	0.000475	CcSEcCtD
Rasagiline—Dermatitis—Estropipate—osteoporosis	0.000269	0.000475	CcSEcCtD
Rasagiline—Anorexia—Conjugated Estrogens—osteoporosis	0.000269	0.000474	CcSEcCtD
Rasagiline—Urticaria—Risedronate—osteoporosis	0.000268	0.000473	CcSEcCtD
Rasagiline—Back pain—Estradiol—osteoporosis	0.000267	0.000472	CcSEcCtD
Rasagiline—Headache—Estropipate—osteoporosis	0.000267	0.000472	CcSEcCtD
Rasagiline—Vomiting—Alendronate—osteoporosis	0.000267	0.000472	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000267	0.000471	CcSEcCtD
Rasagiline—Body temperature increased—Risedronate—osteoporosis	0.000267	0.000471	CcSEcCtD
Rasagiline—Abdominal pain—Risedronate—osteoporosis	0.000267	0.000471	CcSEcCtD
Rasagiline—Muscle spasms—Estradiol—osteoporosis	0.000266	0.000469	CcSEcCtD
Rasagiline—Rash—Alendronate—osteoporosis	0.000265	0.000468	CcSEcCtD
Rasagiline—Insomnia—Zoledronate—osteoporosis	0.000265	0.000468	CcSEcCtD
Rasagiline—Dermatitis—Alendronate—osteoporosis	0.000265	0.000467	CcSEcCtD
Rasagiline—Feeling abnormal—Pamidronate—osteoporosis	0.000264	0.000466	CcSEcCtD
Rasagiline—Hypotension—Conjugated Estrogens—osteoporosis	0.000263	0.000465	CcSEcCtD
Rasagiline—Headache—Alendronate—osteoporosis	0.000263	0.000465	CcSEcCtD
Rasagiline—Paraesthesia—Zoledronate—osteoporosis	0.000263	0.000464	CcSEcCtD
Rasagiline—Vomiting—Raloxifene—osteoporosis	0.000263	0.000464	CcSEcCtD
Rasagiline—Gastrointestinal pain—Pamidronate—osteoporosis	0.000262	0.000463	CcSEcCtD
Rasagiline—Dyspnoea—Zoledronate—osteoporosis	0.000261	0.000461	CcSEcCtD
Rasagiline—Rash—Raloxifene—osteoporosis	0.000261	0.00046	CcSEcCtD
Rasagiline—Dermatitis—Raloxifene—osteoporosis	0.00026	0.00046	CcSEcCtD
Rasagiline—Somnolence—Zoledronate—osteoporosis	0.00026	0.00046	CcSEcCtD
Rasagiline—Vomiting—Ibandronate—osteoporosis	0.00026	0.000459	CcSEcCtD
Rasagiline—Tremor—Estradiol—osteoporosis	0.000259	0.000457	CcSEcCtD
Rasagiline—Headache—Raloxifene—osteoporosis	0.000259	0.000457	CcSEcCtD
Rasagiline—Rash—Ibandronate—osteoporosis	0.000258	0.000455	CcSEcCtD
Rasagiline—Dermatitis—Ibandronate—osteoporosis	0.000258	0.000455	CcSEcCtD
Rasagiline—Dyspepsia—Zoledronate—osteoporosis	0.000258	0.000455	CcSEcCtD
Rasagiline—MAOB—Metabolism—IDH2—osteoporosis	0.000257	0.00175	CbGpPWpGaD
Rasagiline—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000257	0.000453	CcSEcCtD
Rasagiline—Ill-defined disorder—Estradiol—osteoporosis	0.000257	0.000453	CcSEcCtD
Rasagiline—Headache—Ibandronate—osteoporosis	0.000256	0.000453	CcSEcCtD
Rasagiline—Insomnia—Conjugated Estrogens—osteoporosis	0.000255	0.00045	CcSEcCtD
Rasagiline—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000255	0.00045	CcSEcCtD
Rasagiline—Vomiting—Calcitriol—osteoporosis	0.000255	0.00045	CcSEcCtD
Rasagiline—Decreased appetite—Zoledronate—osteoporosis	0.000255	0.000449	CcSEcCtD
Rasagiline—Agitation—Estradiol—osteoporosis	0.000254	0.000449	CcSEcCtD
Rasagiline—BCL2—Apoptosis—TNF—osteoporosis	0.000254	0.00173	CbGpPWpGaD
Rasagiline—Nausea—Estropipate—osteoporosis	0.000253	0.000447	CcSEcCtD
Rasagiline—Body temperature increased—Pamidronate—osteoporosis	0.000253	0.000447	CcSEcCtD
Rasagiline—Abdominal pain—Pamidronate—osteoporosis	0.000253	0.000447	CcSEcCtD
Rasagiline—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000253	0.000447	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000253	0.000446	CcSEcCtD
Rasagiline—Rash—Calcitriol—osteoporosis	0.000253	0.000446	CcSEcCtD
Rasagiline—Dermatitis—Calcitriol—osteoporosis	0.000252	0.000445	CcSEcCtD
Rasagiline—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000251	0.000444	CcSEcCtD
Rasagiline—Headache—Calcitriol—osteoporosis	0.000251	0.000443	CcSEcCtD
Rasagiline—Somnolence—Conjugated Estrogens—osteoporosis	0.000251	0.000443	CcSEcCtD
Rasagiline—Constipation—Zoledronate—osteoporosis	0.00025	0.000442	CcSEcCtD
Rasagiline—Nausea—Alendronate—osteoporosis	0.00025	0.000441	CcSEcCtD
Rasagiline—Malaise—Estradiol—osteoporosis	0.000249	0.00044	CcSEcCtD
Rasagiline—Hypersensitivity—Risedronate—osteoporosis	0.000248	0.000439	CcSEcCtD
Rasagiline—Vertigo—Estradiol—osteoporosis	0.000248	0.000439	CcSEcCtD
Rasagiline—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000248	0.000438	CcSEcCtD
Rasagiline—Asthenia—Ethinyl Estradiol—osteoporosis	0.000248	0.000438	CcSEcCtD
Rasagiline—Syncope—Estradiol—osteoporosis	0.000248	0.000438	CcSEcCtD
Rasagiline—BCL2—Immune System—RAP1A—osteoporosis	0.000247	0.00168	CbGpPWpGaD
Rasagiline—Nausea—Raloxifene—osteoporosis	0.000245	0.000433	CcSEcCtD
Rasagiline—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000245	0.000433	CcSEcCtD
Rasagiline—BCL2—Immune System—CTSK—osteoporosis	0.000245	0.00167	CbGpPWpGaD
Rasagiline—Pruritus—Ethinyl Estradiol—osteoporosis	0.000245	0.000432	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000243	0.00043	CcSEcCtD
Rasagiline—Nausea—Ibandronate—osteoporosis	0.000243	0.000429	CcSEcCtD
Rasagiline—Loss of consciousness—Estradiol—osteoporosis	0.000243	0.000429	CcSEcCtD
Rasagiline—MAOB—Metabolism—CYP27A1—osteoporosis	0.000242	0.00164	CbGpPWpGaD
Rasagiline—Asthenia—Risedronate—osteoporosis	0.000242	0.000427	CcSEcCtD
Rasagiline—Feeling abnormal—Zoledronate—osteoporosis	0.000241	0.000426	CcSEcCtD
Rasagiline—Cough—Estradiol—osteoporosis	0.000241	0.000426	CcSEcCtD
Rasagiline—Constipation—Conjugated Estrogens—osteoporosis	0.000241	0.000426	CcSEcCtD
Rasagiline—BCL2—Immune System—NFATC1—osteoporosis	0.000241	0.00164	CbGpPWpGaD
Rasagiline—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.00024	0.00163	CbGpPWpGaD
Rasagiline—Gastrointestinal pain—Zoledronate—osteoporosis	0.000239	0.000423	CcSEcCtD
Rasagiline—Hypertension—Estradiol—osteoporosis	0.000239	0.000421	CcSEcCtD
Rasagiline—Pruritus—Risedronate—osteoporosis	0.000239	0.000421	CcSEcCtD
Rasagiline—Nausea—Calcitriol—osteoporosis	0.000238	0.00042	CcSEcCtD
Rasagiline—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000237	0.000418	CcSEcCtD
Rasagiline—Hypersensitivity—Pamidronate—osteoporosis	0.000236	0.000417	CcSEcCtD
Rasagiline—Arthralgia—Estradiol—osteoporosis	0.000235	0.000416	CcSEcCtD
Rasagiline—Chest pain—Estradiol—osteoporosis	0.000235	0.000416	CcSEcCtD
Rasagiline—MAOB—Metabolism—ACP5—osteoporosis	0.000235	0.0016	CbGpPWpGaD
Rasagiline—Anxiety—Estradiol—osteoporosis	0.000235	0.000414	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000234	0.000413	CcSEcCtD
Rasagiline—Urticaria—Zoledronate—osteoporosis	0.000233	0.000411	CcSEcCtD
Rasagiline—Discomfort—Estradiol—osteoporosis	0.000233	0.000411	CcSEcCtD
Rasagiline—Body temperature increased—Zoledronate—osteoporosis	0.000231	0.000409	CcSEcCtD
Rasagiline—Abdominal pain—Zoledronate—osteoporosis	0.000231	0.000409	CcSEcCtD
Rasagiline—Diarrhoea—Risedronate—osteoporosis	0.000231	0.000407	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	0.000231	0.00157	CbGpPWpGaD
Rasagiline—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000231	0.000407	CcSEcCtD
Rasagiline—Dry mouth—Estradiol—osteoporosis	0.00023	0.000406	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	0.00023	0.00156	CbGpPWpGaD
Rasagiline—Asthenia—Pamidronate—osteoporosis	0.00023	0.000406	CcSEcCtD
Rasagiline—Dizziness—Ethinyl Estradiol—osteoporosis	0.000229	0.000404	CcSEcCtD
Rasagiline—Confusional state—Estradiol—osteoporosis	0.000227	0.000402	CcSEcCtD
Rasagiline—Pruritus—Pamidronate—osteoporosis	0.000227	0.0004	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—AGER—osteoporosis	0.000225	0.00153	CbGpPWpGaD
Rasagiline—Infection—Estradiol—osteoporosis	0.000224	0.000396	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—ADCY5—osteoporosis	0.000224	0.00152	CbGpPWpGaD
Rasagiline—Urticaria—Conjugated Estrogens—osteoporosis	0.000224	0.000395	CcSEcCtD
Rasagiline—Dizziness—Risedronate—osteoporosis	0.000223	0.000394	CcSEcCtD
Rasagiline—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000223	0.000393	CcSEcCtD
Rasagiline—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000223	0.000393	CcSEcCtD
Rasagiline—Shock—Estradiol—osteoporosis	0.000222	0.000392	CcSEcCtD
Rasagiline—Nervous system disorder—Estradiol—osteoporosis	0.000221	0.000391	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—osteoporosis	0.00022	0.0015	CbGpPWpGaD
Rasagiline—Vomiting—Ethinyl Estradiol—osteoporosis	0.00022	0.000388	CcSEcCtD
Rasagiline—Diarrhoea—Pamidronate—osteoporosis	0.000219	0.000387	CcSEcCtD
Rasagiline—Skin disorder—Estradiol—osteoporosis	0.000219	0.000387	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000219	0.00149	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—TPI1—osteoporosis	0.000219	0.00149	CbGpPWpGaD
Rasagiline—Hyperhidrosis—Estradiol—osteoporosis	0.000218	0.000385	CcSEcCtD
Rasagiline—Rash—Ethinyl Estradiol—osteoporosis	0.000218	0.000385	CcSEcCtD
Rasagiline—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000218	0.000385	CcSEcCtD
Rasagiline—Headache—Ethinyl Estradiol—osteoporosis	0.000217	0.000383	CcSEcCtD
Rasagiline—Hypersensitivity—Zoledronate—osteoporosis	0.000216	0.000381	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	0.000215	0.00146	CbGpPWpGaD
Rasagiline—Vomiting—Risedronate—osteoporosis	0.000214	0.000379	CcSEcCtD
Rasagiline—Rash—Risedronate—osteoporosis	0.000213	0.000375	CcSEcCtD
Rasagiline—Dermatitis—Risedronate—osteoporosis	0.000212	0.000375	CcSEcCtD
Rasagiline—Dizziness—Pamidronate—osteoporosis	0.000212	0.000374	CcSEcCtD
Rasagiline—Headache—Risedronate—osteoporosis	0.000211	0.000373	CcSEcCtD
Rasagiline—Asthenia—Zoledronate—osteoporosis	0.00021	0.000371	CcSEcCtD
Rasagiline—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000208	0.000367	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000207	0.00141	CbGpPWpGaD
Rasagiline—Pruritus—Zoledronate—osteoporosis	0.000207	0.000366	CcSEcCtD
Rasagiline—MAOB—Metabolism—P4HB—osteoporosis	0.000206	0.0014	CbGpPWpGaD
Rasagiline—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000206	0.000363	CcSEcCtD
Rasagiline—Nausea—Ethinyl Estradiol—osteoporosis	0.000205	0.000363	CcSEcCtD
Rasagiline—Insomnia—Estradiol—osteoporosis	0.000204	0.00036	CcSEcCtD
Rasagiline—Vomiting—Pamidronate—osteoporosis	0.000204	0.00036	CcSEcCtD
Rasagiline—Paraesthesia—Estradiol—osteoporosis	0.000203	0.000358	CcSEcCtD
Rasagiline—Asthenia—Conjugated Estrogens—osteoporosis	0.000202	0.000357	CcSEcCtD
Rasagiline—Rash—Pamidronate—osteoporosis	0.000202	0.000357	CcSEcCtD
Rasagiline—MAOB—Metabolism—GAPDH—osteoporosis	0.000202	0.00137	CbGpPWpGaD
Rasagiline—Dermatitis—Pamidronate—osteoporosis	0.000202	0.000357	CcSEcCtD
Rasagiline—Dyspnoea—Estradiol—osteoporosis	0.000201	0.000355	CcSEcCtD
Rasagiline—Headache—Pamidronate—osteoporosis	0.000201	0.000355	CcSEcCtD
Rasagiline—Somnolence—Estradiol—osteoporosis	0.000201	0.000354	CcSEcCtD
Rasagiline—Diarrhoea—Zoledronate—osteoporosis	0.0002	0.000354	CcSEcCtD
Rasagiline—Nausea—Risedronate—osteoporosis	0.0002	0.000354	CcSEcCtD
Rasagiline—Pruritus—Conjugated Estrogens—osteoporosis	0.000199	0.000352	CcSEcCtD
Rasagiline—Dyspepsia—Estradiol—osteoporosis	0.000199	0.000351	CcSEcCtD
Rasagiline—BCL2—Immune System—PSMA2—osteoporosis	0.000197	0.00134	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PSMA5—osteoporosis	0.000197	0.00134	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—RAP1A—osteoporosis	0.000197	0.00134	CbGpPWpGaD
Rasagiline—Decreased appetite—Estradiol—osteoporosis	0.000196	0.000346	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—IRS2—osteoporosis	0.000196	0.00133	CbGpPWpGaD
Rasagiline—Gastrointestinal disorder—Estradiol—osteoporosis	0.000195	0.000344	CcSEcCtD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—POMC—osteoporosis	0.000195	0.00132	CbGpPWpGaD
Rasagiline—Dizziness—Zoledronate—osteoporosis	0.000194	0.000342	CcSEcCtD
Rasagiline—Constipation—Estradiol—osteoporosis	0.000193	0.000341	CcSEcCtD
Rasagiline—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000193	0.000341	CcSEcCtD
Rasagiline—Nausea—Pamidronate—osteoporosis	0.00019	0.000336	CcSEcCtD
Rasagiline—Dizziness—Conjugated Estrogens—osteoporosis	0.000186	0.000329	CcSEcCtD
Rasagiline—Vomiting—Zoledronate—osteoporosis	0.000186	0.000329	CcSEcCtD
Rasagiline—Feeling abnormal—Estradiol—osteoporosis	0.000186	0.000328	CcSEcCtD
Rasagiline—Rash—Zoledronate—osteoporosis	0.000185	0.000326	CcSEcCtD
Rasagiline—Gastrointestinal pain—Estradiol—osteoporosis	0.000184	0.000326	CcSEcCtD
Rasagiline—Dermatitis—Zoledronate—osteoporosis	0.000184	0.000326	CcSEcCtD
Rasagiline—Headache—Zoledronate—osteoporosis	0.000183	0.000324	CcSEcCtD
Rasagiline—Vomiting—Conjugated Estrogens—osteoporosis	0.000179	0.000316	CcSEcCtD
Rasagiline—Urticaria—Estradiol—osteoporosis	0.000179	0.000316	CcSEcCtD
Rasagiline—Abdominal pain—Estradiol—osteoporosis	0.000178	0.000315	CcSEcCtD
Rasagiline—Body temperature increased—Estradiol—osteoporosis	0.000178	0.000315	CcSEcCtD
Rasagiline—Rash—Conjugated Estrogens—osteoporosis	0.000178	0.000314	CcSEcCtD
Rasagiline—Dermatitis—Conjugated Estrogens—osteoporosis	0.000178	0.000314	CcSEcCtD
Rasagiline—Headache—Conjugated Estrogens—osteoporosis	0.000177	0.000312	CcSEcCtD
Rasagiline—Nausea—Zoledronate—osteoporosis	0.000174	0.000307	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—CYP19A1—osteoporosis	0.000172	0.00117	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—MYC—osteoporosis	0.000172	0.00117	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—osteoporosis	0.000171	0.00116	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IRS1—osteoporosis	0.000171	0.00116	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—CYP19A1—osteoporosis	0.00017	0.00115	CbGpPWpGaD
Rasagiline—Nausea—Conjugated Estrogens—osteoporosis	0.000167	0.000296	CcSEcCtD
Rasagiline—BCL2—Immune System—KL—osteoporosis	0.000167	0.00113	CbGpPWpGaD
Rasagiline—Hypersensitivity—Estradiol—osteoporosis	0.000166	0.000294	CcSEcCtD
Rasagiline—Asthenia—Estradiol—osteoporosis	0.000162	0.000286	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	0.000161	0.0011	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IL6R—osteoporosis	0.000161	0.00109	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—TNF—osteoporosis	0.00016	0.00109	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—osteoporosis	0.00016	0.00109	CbGpPWpGaD
Rasagiline—Pruritus—Estradiol—osteoporosis	0.00016	0.000282	CcSEcCtD
Rasagiline—MAOB—Metabolism—ENO1—osteoporosis	0.000159	0.00108	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	0.000157	0.00107	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PSMA5—osteoporosis	0.000157	0.00107	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PSMA2—osteoporosis	0.000157	0.00107	CbGpPWpGaD
Rasagiline—Diarrhoea—Estradiol—osteoporosis	0.000154	0.000273	CcSEcCtD
Rasagiline—Dizziness—Estradiol—osteoporosis	0.000149	0.000263	CcSEcCtD
Rasagiline—Vomiting—Estradiol—osteoporosis	0.000143	0.000253	CcSEcCtD
Rasagiline—Rash—Estradiol—osteoporosis	0.000142	0.000251	CcSEcCtD
Rasagiline—Dermatitis—Estradiol—osteoporosis	0.000142	0.000251	CcSEcCtD
Rasagiline—Headache—Estradiol—osteoporosis	0.000141	0.00025	CcSEcCtD
Rasagiline—Nausea—Estradiol—osteoporosis	0.000134	0.000237	CcSEcCtD
Rasagiline—BCL2—Immune System—AGER—osteoporosis	0.000131	0.00089	CbGpPWpGaD
Rasagiline—BCL2—Immune System—ADCY5—osteoporosis	0.00013	0.000887	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYP19A1—osteoporosis	0.000127	0.000864	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	0.000126	0.000855	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IRS2—osteoporosis	0.000114	0.000776	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	0.000107	0.000727	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ADCY5—osteoporosis	0.000104	0.000706	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GPX1—osteoporosis	0.000103	0.000704	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—POMC—osteoporosis	0.000103	0.000703	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IRS1—osteoporosis	9.96e-05	0.000678	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PKM—osteoporosis	9.75e-05	0.000663	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—FDPS—osteoporosis	9.75e-05	0.000663	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—MTHFR—osteoporosis	9.55e-05	0.000649	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL6R—osteoporosis	9.36e-05	0.000636	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GPD2—osteoporosis	9.24e-05	0.000628	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PGLS—osteoporosis	9.24e-05	0.000628	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ATIC—osteoporosis	8.45e-05	0.000575	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PNP—osteoporosis	8.45e-05	0.000575	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—POMC—osteoporosis	7.64e-05	0.000519	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CA2—osteoporosis	7.19e-05	0.000489	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—OXCT1—osteoporosis	7.19e-05	0.000489	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IL6—osteoporosis	7.16e-05	0.000487	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL1B—osteoporosis	7.12e-05	0.000484	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—MGLL—osteoporosis	7e-05	0.000476	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	6.6e-05	0.000449	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—IDH2—osteoporosis	5.95e-05	0.000405	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP27A1—osteoporosis	5.6e-05	0.000381	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ACP5—osteoporosis	5.45e-05	0.00037	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	5.38e-05	0.000366	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—TPI1—osteoporosis	5.06e-05	0.000344	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—P4HB—osteoporosis	4.76e-05	0.000324	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GAPDH—osteoporosis	4.67e-05	0.000318	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—RAP1A—osteoporosis	4.55e-05	0.000309	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL6—osteoporosis	4.17e-05	0.000284	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	3.97e-05	0.00027	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ENO1—osteoporosis	3.68e-05	0.00025	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PSMA2—osteoporosis	3.63e-05	0.000246	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PSMA5—osteoporosis	3.63e-05	0.000246	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP19A1—osteoporosis	2.94e-05	0.0002	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ADCY5—osteoporosis	2.4e-05	0.000163	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GPX1—osteoporosis	2.39e-05	0.000163	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—MTHFR—osteoporosis	2.21e-05	0.00015	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—POMC—osteoporosis	1.77e-05	0.00012	CbGpPWpGaD
